Vascular involvement in systemic sclerosis (scleroderma)
Debendra Pattanaik1, Monica Brown2, Arnold E Postlethwaite1
1Division of Connective Tissue Diseases, Department of Medicine; 2Section of Pediatric Rheumatology Department of Pediatrics, University of Tennessee Health Science Center, and Department of Veterans Affairs Medical Center, Memphis, TN, USA
Abstract: Systemic sclerosis (SSc) is an acquired multiorgan connective tissue disease with variable mortality and morbidity dictated by clinical subset type. The etiology of the basic disease and pathogenesis of the systemic autoimmunity, fibrosis, and fibroproliferative vasculopathy are unknown and debated. In this review, the spectrum of vascular abnormalities and the options currently available to treat the vascular manifestations of SSc are discussed. Also discussed is how the hallmark pathologies (ie, how autoimmunity, vasculopathy, and fibrosis of the disease) might be effected and interconnected with modulatory input from lysophospholipids, sphingosine 1-phosphate, and lysophosphatidic acid.
Keywords: fibrosis, autoimmunity, vasculopathy, S1P, LPA
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php